FI1849470T4 - Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää - Google Patents

Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää Download PDF

Info

Publication number
FI1849470T4
FI1849470T4 FIEP06712292.9T FI06712292T FI1849470T4 FI 1849470 T4 FI1849470 T4 FI 1849470T4 FI 06712292 T FI06712292 T FI 06712292T FI 1849470 T4 FI1849470 T4 FI 1849470T4
Authority
FI
Finland
Prior art keywords
cancer
drug
therapeutic
dose
day
Prior art date
Application number
FIEP06712292.9T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI1849470(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of FI1849470T4 publication Critical patent/FI1849470T4/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP06712292.9T 2005-01-26 2017-09-06 Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää FI1849470T4 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (1)

Publication Number Publication Date
FI1849470T4 true FI1849470T4 (fi) 2024-03-22

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP06712292.9T FI1849470T4 (fi) 2005-01-26 2017-09-06 Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää

Country Status (20)

Country Link
EP (1) EP1849470B2 (enExample)
JP (1) JP5576591B2 (enExample)
KR (1) KR101468216B1 (enExample)
AU (1) AU2006209547C1 (enExample)
BE (1) BE2017C028I2 (enExample)
CA (1) CA2594713A1 (enExample)
CY (2) CY2017029I2 (enExample)
DK (1) DK1849470T4 (enExample)
ES (1) ES2630002T5 (enExample)
FI (1) FI1849470T4 (enExample)
FR (1) FR17C1028I2 (enExample)
HU (2) HUE033306T2 (enExample)
LT (2) LT1849470T (enExample)
LU (1) LUC00036I2 (enExample)
NL (1) NL300889I2 (enExample)
PL (1) PL1849470T5 (enExample)
PT (1) PT1849470T (enExample)
SI (1) SI1849470T2 (enExample)
TW (1) TWI362265B (enExample)
WO (1) WO2006080327A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
PL2746404T3 (pl) 2011-08-16 2018-04-30 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN104349779A (zh) * 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
US9616081B2 (en) * 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
UA114840C2 (uk) * 2013-03-27 2017-08-10 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний агент, який включає гідрат гідрохлориду іринотекану
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014316030C1 (en) 2013-09-06 2024-08-15 Les Laboratoires Servier Antitumor agent and antitumor effect enhancer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3693019A1 (en) 2016-01-08 2020-08-12 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator
KR102412690B1 (ko) 2016-02-05 2022-06-23 다이호야쿠힌고교 가부시키가이샤 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3088757B2 (ja) 1995-03-29 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤
EP0884051B1 (en) * 1996-09-24 2004-12-15 Taiho Pharmaceutical Company Limited Cancerous metastasis inhibitors containing uracil derivatives
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor

Also Published As

Publication number Publication date
RU2007132181A (ru) 2009-03-10
JPWO2006080327A1 (ja) 2008-06-19
LUC00036I2 (enExample) 2017-12-01
FR17C1028I2 (fr) 2018-11-02
LUC00036I1 (enExample) 2017-10-02
PL1849470T3 (pl) 2017-11-30
ES2630002T5 (es) 2024-09-19
DK1849470T4 (en) 2024-04-02
BE2017C028I2 (enExample) 2025-09-10
CY2017029I1 (el) 2018-02-14
JP5576591B2 (ja) 2014-08-20
EP1849470A4 (en) 2010-12-08
LTC1849470I2 (lt) 2019-10-25
ES2630002T3 (es) 2017-08-17
AU2006209547A1 (en) 2006-08-03
TW200637562A (en) 2006-11-01
CY2017029I2 (el) 2018-02-14
SI1849470T2 (sl) 2024-05-31
TWI362265B (en) 2012-04-21
SI1849470T1 (sl) 2017-10-30
PL1849470T5 (pl) 2024-06-10
NL300889I2 (nl) 2018-01-16
AU2006209547B2 (en) 2011-05-26
AU2006209547C1 (en) 2022-04-07
EP1849470A1 (en) 2007-10-31
EP1849470B2 (en) 2024-03-20
HUS1700032I1 (hu) 2017-09-28
NL300889I1 (nl) 2017-08-14
CA2594713A1 (en) 2006-08-03
PT1849470T (pt) 2017-09-22
LTPA2017024I1 (lt) 2017-08-10
CY1119393T1 (el) 2018-02-14
EP1849470B1 (en) 2017-06-21
WO2006080327A1 (ja) 2006-08-03
KR101468216B1 (ko) 2014-12-03
LT1849470T (lt) 2017-07-25
FR17C1028I1 (enExample) 2017-09-29
HUE033306T2 (hu) 2017-11-28
KR20070104559A (ko) 2007-10-26
DK1849470T3 (en) 2017-08-14
RU2394581C2 (ru) 2010-07-20

Similar Documents

Publication Publication Date Title
JP5576591B2 (ja) α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
JP2006515883A5 (enExample)
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
US20110015135A1 (en) Antitumoral Treatments
JP2009539769A5 (enExample)
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
EP1689404B9 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
US20100240595A1 (en) Improved Antitumoral Treatments
JP2011514356A5 (enExample)
JP6458007B2 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
JP6488280B2 (ja) タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
Chang et al. Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer
JP2015199678A (ja) ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
JP2015199677A (ja) ノギテカン塩酸塩を含有する抗腫瘍剤及び抗腫瘍効果増強剤
KR20070029165A (ko) 에포틸론과 카보플라틴을 사용하는 병행 요법
JP2013166702A (ja) キナーゼ阻害剤を組み合わせた抗腫瘍剤
NZ740252A (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate
HK1177889B (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
CN103933539A (zh) 一种含有四环素的药物组合物及其应用